BioCompute Object: Difference between revisions

Revision as of 14:11, 20 May 2020

Revision as of 16:01, 22 June 2020

Line 24:

The '''BioCompute Object (BCO) Project''' is a community-driven initiative to build a framework for standardizing and sharing computations and analyses generated from [[High-throughput sequencing]] (HTS), also referred to as [[next-generation sequencing]] (NGS) or [[massively parallel sequencing]] (MPS).<ref>Simonyan V, Goecks J, Mazumder R. Biocompute Objects—A Step towards Evaluation and Validation of Biomedical Scientific Computations. PDA journal of pharmaceutical science and technology. 2017;71(2):136-146. doi:10.5731/pdajpst.2016.006734.</ref> Originally started as a collaborative contract between the [[George Washington University]] and the [[Food and Drug Administration]], the project has grown to include over 20 universities, biotechnology companies, public-private partnerships and pharmaceutical companies including Seven Bridges and [[Harvard Medical School]].<ref>{{Cite web|url=https://www.europeanpharmaceuticalreview.com/news/67524/biocompute-genomic-data/|title=BioCompute Objects specifications to advance genomic data analysis|website=www.europeanpharmaceuticalreview.com|language=en|access-date=2017-12-21}}</ref> The BCO aims to ease the exchange of HTS workflows between various organizations, such as the FDA, pharmaceutical companies, contract research organizations, bioinformatic platform providers, and academic researchers. TheDue projectto hasthe ansensitive illusionnature of supportregulatory duefilings, few direct references to amaterial convolutedcan systembe ofpublished. self-citationsHowever, andthe referencesproject is currently funded to resourcetrain announcementsFDA ratherReviewers thanand administrators to completedread projects.and Thisinterpret isBCOs, aand commoncurrently hallmarkhas of4 publications [[High-performanceeither Integratedsubmitted Virtualor Environment|HIVE]]nearly projectssubmitted.

== Background ==